Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTX
Previous Symbol
CUSIPN/A
Phone847-871-0377
Debt
Debt-to-Equity RatioN/A
Current Ratio21.85
Quick Ratio21.85
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.96 million
Price / Sales135.08
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees64
Outstanding Shares33,500,000
Market Cap$740.63 million
OptionableNot Optionable
Aptinyx (NASDAQ:APTX) Frequently Asked Questions
What is Aptinyx's stock symbol?
Aptinyx trades on the NASDAQ under the ticker symbol "APTX."
How were Aptinyx's earnings last quarter?
Aptinyx Inc (NASDAQ:APTX) issued its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $0.58. The company earned $0.94 million during the quarter, compared to the consensus estimate of $1.10 million. View Aptinyx's Earnings History.
When is Aptinyx's next earnings date?
What price target have analysts set for APTX?
5 Wall Street analysts have issued 1-year price targets for Aptinyx's shares. Their predictions range from $30.00 to $40.00. On average, they anticipate Aptinyx's share price to reach $34.25 in the next year. This suggests a possible upside of 71.3% from the stock's current price. View Analyst Price Targets for Aptinyx.
What is the consensus analysts' recommendation for Aptinyx?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.
Has Aptinyx been receiving favorable news coverage?
Headlines about APTX stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aptinyx earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the stock's share price in the next few days.
Who are some of Aptinyx's key competitors?
Some companies that are related to Aptinyx include Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Allakos (ALLK), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Endo International (ENDP), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Myokardia (MYOK), Xencor (XNCR), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), Endocyte (ECYT) and Heron Therapeutics (HRTX).
Who are Aptinyx's key executives?
Aptinyx's management team includes the folowing people:
- Mr. Norbert G. Riedel, Pres, CEO & Director (Age 60)
- Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 67)
- Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
- Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 42)
- Mr. Nicholas C. Smith, Director of Corp. Devel.
When did Aptinyx IPO?
(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
When did the company's lock-up period expire?
Aptinyx's lock-up period expired on Tuesday, December 18th. Aptinyx had issued 6,399,999 shares in its initial public offering on June 21st. The total size of the offering was $102,399,984 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.
Who are Aptinyx's major shareholders?
Aptinyx's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Partner Fund Management L.P. (5.24%), Victory Capital Management Inc. (2.41%), BlackRock Inc. (2.30%), NF Trinity Capital Hong Kong Ltd (1.82%), Citadel Advisors LLC (0.94%) and Vanguard Group Inc. (0.89%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna and Norbert G Riedel. View Institutional Ownership Trends for Aptinyx.
Which institutional investors are selling Aptinyx stock?
APTX stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, NF Trinity Capital Hong Kong Ltd and Essex Investment Management Co. LLC. View Insider Buying and Selling for Aptinyx.
Which institutional investors are buying Aptinyx stock?
APTX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Partner Fund Management L.P., Vanguard Group Inc, Vanguard Group Inc., Citadel Advisors LLC, Victory Capital Management Inc., Bank of New York Mellon Corp and TIAA CREF Investment Management LLC. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna and Norbert G Riedel. View Insider Buying and Selling for Aptinyx.
How do I buy shares of Aptinyx?
Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptinyx's stock price today?
One share of APTX stock can currently be purchased for approximately $20.00.
How big of a company is Aptinyx?
Aptinyx has a market capitalization of $740.63 million and generates $4.96 million in revenue each year. Aptinyx employs 64 workers across the globe.
What is Aptinyx's official website?
How can I contact Aptinyx?
Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]
MarketBeat Community Rating for Aptinyx (NASDAQ APTX)
MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
